Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Nemer who wrote (4295)	7/13/1998 7:49:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

PFE Report: Motley Fool Cash King Report BigKNY3 Pfizer (NYSE: PFE) announced 2nd-quarter earnings that ran a few pennies above estimates. The company benefited from an estimate-stomping $411 million in sales from its male impotency treatment, Viagra. Not overlooked by the investing community, that figure includes just $2 million of international sales. The future looks very bright for this drug. But Pfizer is much more than Viagra, which accounted for just 11% of the company's total sales for the quarter. Let's take a look at the earnings box: 2Q 1998 2Q 1997 Sales $3.6 bil. $2.9 bil. Earnings $628 mil. $457 mil. EPS $0.47 $0.35 Take a breath -- there are some numbers oncoming. Pfizer's second quarter marked sales growth of 25%, earnings growth of 38%, and growth in earnings per share of 34%. Simultaneously, Pfizer inched its gross margins up to 83.9% from 82.5%, and its net margins to 17.3% from 15.7%. Spending on research & development for the quarter increased 25%, to $574 million, in line with sales growth. Pfizer's report exceeded our expectations, showed improvement in our critical Cash-King measures, and we believe confirms our approach to the markets. We'll get a better look at the financial strength of the quarter when the company releases its balance sheet in late July. Click here now though pfor management's comments and pfor the company's 2nd Quarter income statement: Pfizer's 2nd Quarter Earnings Report. Pfizer is now up more than p43% pfor us since our purchase in Pfebruary. Given Pfizer's perpformance in 1998, we're considering renaming a lot of stupf around here now. The Motley Pfool, The Cash-King Portpfolio, pfree registration to our message boards, the word Pfriday, and the number pfour -- to name a pfew. We're just considering it!